[go: up one dir, main page]

WO2005095399A3 - Derives pyrrolo (2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases - Google Patents

Derives pyrrolo (2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases Download PDF

Info

Publication number
WO2005095399A3
WO2005095399A3 PCT/FR2005/000773 FR2005000773W WO2005095399A3 WO 2005095399 A3 WO2005095399 A3 WO 2005095399A3 FR 2005000773 W FR2005000773 W FR 2005000773W WO 2005095399 A3 WO2005095399 A3 WO 2005095399A3
Authority
WO
WIPO (PCT)
Prior art keywords
nr7r8
alkyl
alkoxy
preparation
kinase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2005/000773
Other languages
English (en)
Other versions
WO2005095399A2 (fr
Inventor
Sylvie Wentzler
Youssef El-Ahmad
Bruno Filoche-Romme
Conception Nemecek
Corinne Venot
Augustin Hittinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0509564-6A priority Critical patent/BRPI0509564A/pt
Priority to EP05746934A priority patent/EP1732546A2/fr
Priority to MXPA06011161A priority patent/MXPA06011161A/es
Priority to AU2005229452A priority patent/AU2005229452A1/en
Priority to JP2007505596A priority patent/JP4841543B2/ja
Priority to CA002558923A priority patent/CA2558923A1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of WO2005095399A2 publication Critical patent/WO2005095399A2/fr
Publication of WO2005095399A3 publication Critical patent/WO2005095399A3/fr
Priority to IL178310A priority patent/IL178310A0/en
Priority to US11/541,051 priority patent/US7528147B2/en
Anticipated expiration legal-status Critical
Priority to US12/410,135 priority patent/US7968566B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne les nouveaux produits de formule (I) : dans laquelle R représente hydrogène ou est choisi parmi R2 et R3, R1 représente alkényle ou alkyle éventuellement substitué par -CO-NR7R8, -NR7R8, carboxy, hydroxyle, alcoxy ou halogène, R2 et R3 identiques ou différents représentent alkyle ou -O-alkyle éventuellement substitués par -CO-NR7R8, -NR7R8, alcoxy, alcoxy-NR7R8, carboxy ou phényle, R4, R5 et R6 identiques ou différents représentent hydrogène, halogène, cyano, amino, alcoxy ou alkyle, R4 représentant de plus -CH=O, -CH=N-OH et -CH2NHOH; R7 et R8 représentent notamment hydrogène, alkyle, alkényle, cycloalkyle, cycloalkényle, hétérocycloalkyle, aryle et hétéroaryle ou bien R7 et R8 forment avec l'atome d'azote un hétérocycle éventuellement substitué, ces produits étant sous toutes les formes isomères et les sels, à titre de médicaments.
PCT/FR2005/000773 2004-03-31 2005-03-30 Derives pyrrolo (2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases Ceased WO2005095399A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP05746934A EP1732546A2 (fr) 2004-03-31 2005-03-30 Nouveaux derives pyrrolo(2,3-b)pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
MXPA06011161A MXPA06011161A (es) 2004-03-31 2005-03-30 Nuevos derivados de la pirrolo(2,3-b)piridina, su preparacion y su utilizacion farmaceutica como inhibidores de cinasas.
AU2005229452A AU2005229452A1 (en) 2004-03-31 2005-03-30 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
JP2007505596A JP4841543B2 (ja) 2004-03-31 2005-03-30 新規なピロロ（２，３−ｂ）ピリジン誘導体、製造およびキナーゼ阻害薬の形態でのそれの医薬的使用
CA002558923A CA2558923A1 (fr) 2004-03-31 2005-03-30 Derives pyrrolo (2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
BRPI0509564-6A BRPI0509564A (pt) 2004-03-31 2005-03-30 derivados pirrolo(2,3-b)piridina, respectivo preparo e respectiva utilização farmacêutica como inibidores de quinases
IL178310A IL178310A0 (en) 2004-03-31 2006-09-26 Novel pyrrolo (2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
US11/541,051 US7528147B2 (en) 2004-03-31 2006-09-29 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
US12/410,135 US7968566B2 (en) 2004-03-31 2009-03-24 Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0403354A FR2868422B1 (fr) 2004-03-31 2004-03-31 Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR0403354 2004-03-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/541,051 Continuation US7528147B2 (en) 2004-03-31 2006-09-29 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors

Publications (2)

Publication Number Publication Date
WO2005095399A2 WO2005095399A2 (fr) 2005-10-13
WO2005095399A3 true WO2005095399A3 (fr) 2006-06-01

Family

ID=34946084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/000773 Ceased WO2005095399A2 (fr) 2004-03-31 2005-03-30 Derives pyrrolo (2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Country Status (15)

Country Link
US (2) US7528147B2 (fr)
EP (1) EP1732546A2 (fr)
JP (1) JP4841543B2 (fr)
KR (1) KR20070014151A (fr)
CN (1) CN1950083A (fr)
AR (1) AR048344A1 (fr)
AU (1) AU2005229452A1 (fr)
BR (1) BRPI0509564A (fr)
CA (1) CA2558923A1 (fr)
FR (1) FR2868422B1 (fr)
IL (1) IL178310A0 (fr)
MX (1) MXPA06011161A (fr)
TW (1) TW200602344A (fr)
UY (1) UY28835A1 (fr)
WO (1) WO2005095399A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868422B1 (fr) * 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CA2774998A1 (fr) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Procedes de modulation de l'autophagie par la modulation de produits geniques inhibant l'autophagie
CN102070638A (zh) * 2009-11-24 2011-05-25 上海药明康德新药开发有限公司 一种六氢-吡咯[3,4-c]吡咯-1-酮衍生物的制备方法
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
WO2015073481A1 (fr) * 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Procédés de préparation d'inhibiteurs de la réplication des virus de la grippe
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN112961159B (zh) * 2020-03-05 2022-07-01 四川大学华西医院 氨基嘧啶并吡唑/吡咯类衍生物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000688A1 (fr) * 2001-06-21 2003-01-03 Aventis Pharma Limited Azaindoles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ519121A (en) * 1999-12-24 2004-05-28 Aventis Pharma Ltd Azaindoles useful as Syk kinase inhibitors
SE0102204D0 (sv) * 2001-06-21 2001-06-21 Leif Isaksson New method
WO2003000690A1 (fr) * 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthese de composes heterocycliques faisant appel a une technologie micro-onde
FR2868422B1 (fr) * 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000688A1 (fr) * 2001-06-21 2003-01-03 Aventis Pharma Limited Azaindoles

Also Published As

Publication number Publication date
US7528147B2 (en) 2009-05-05
JP4841543B2 (ja) 2011-12-21
AU2005229452A1 (en) 2005-10-13
EP1732546A2 (fr) 2006-12-20
KR20070014151A (ko) 2007-01-31
IL178310A0 (en) 2007-02-11
FR2868422A1 (fr) 2005-10-07
TW200602344A (en) 2006-01-16
MXPA06011161A (es) 2007-12-10
US7968566B2 (en) 2011-06-28
FR2868422B1 (fr) 2006-07-14
BRPI0509564A (pt) 2007-09-25
CA2558923A1 (fr) 2005-10-13
JP2007530645A (ja) 2007-11-01
US20090233956A1 (en) 2009-09-17
WO2005095399A2 (fr) 2005-10-13
US20070093480A1 (en) 2007-04-26
AR048344A1 (es) 2006-04-19
CN1950083A (zh) 2007-04-18
UY28835A1 (es) 2005-10-31

Similar Documents

Publication Publication Date Title
WO2003024967A3 (fr) Composes chimiques
TW200738684A (en) Novel sulfated cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
HRP20180483T1 (hr) Spoj kinolona
MY144655A (en) Pyrimidine urea derivatives as kinase inhibitors
UA95976C2 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
NO20074071L (no) Hydrazinometyl, hydrozonometyl og 5-leddete heterocykliske forbindelser som virker som MTOR inhibitorer og anvendelse derav som anti-cancer midler
MX2009011213A (es) Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica.
WO2008145839A8 (fr) Dérivés de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur préparation et leur application en thérapeutique
NO20072053L (no) Nye bis-azaindolderivater, fremstilling og farmasoytisk anvendelse derav som kinaseinhibitorer
WO2010007316A3 (fr) NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
TW200738685A (en) Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
WO2007143422A3 (fr) Composés de pyridyl amide substitués utilisés comme modulateurs du récepteur de l'histamine h3
WO2005095395A3 (fr) Derives de tetrahydronaphtyridine et procede d’elaboration desdits derives
WO2008126901A1 (fr) Composé hétérocyclique contenant de l'azote et composition pharmaceutique le contenant
WO2009118473A3 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
PH12012501004A1 (en) Pyridine-pyridinone derivatives, preparation and therapeutic use thereof
WO2005095399A3 (fr) Derives pyrrolo (2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2009502953A5 (fr)
HRP20221277T1 (hr) Kondenzirani heterociklični spoj
WO2008046982A3 (fr) Nouveaux derives imidazolones, leur preparation a titre de medicaments, compositions pharmaceutiques, utilisation comme inhibiteurs de proteines kinases notamment cdc7
WO2006136837A3 (fr) Composes pharmaceutiques
NO20063330L (no) Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2558923

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 178310

Country of ref document: IL

Ref document number: 2005229452

Country of ref document: AU

Ref document number: 2811/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/011161

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 11541051

Country of ref document: US

Ref document number: 2007505596

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005746934

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 1020067021575

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005229452

Country of ref document: AU

Date of ref document: 20050330

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005229452

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580013791.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005746934

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067021575

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 11541051

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0509564

Country of ref document: BR